Sinopharm Group Co. Ltd.
http://ir.sinopharmgroup.com.cn/html/index.php
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sinopharm Group Co. Ltd.
Beijing Expands COVID Testing; Stringent New COVID Policy Coming?
Beijing expands mass testing to more areas and Shanghai’s case fatally rate raises questions amid China deals with the worst outbreak in two years.
Boosters Miss Growth Expectations Despite China COVID Surge
While two Chinese companies gained domestic approvals for their recombinant protein and adenovirus-based COVID-19 shots as heterologous boosters in February, these currently only account for roughly 21% of all booster shots, showing the continued predominance of inactivated virus-based technology in the country.
Pfizer Signs Paxlovid Agreement As China Cases Soar
Pfizer has signed up with a state-owned enterprise for the distribution of its recently approved oral antiviral for COVID-19 in China, where daily case counts are surging amid some tightening restrictions.
New Global Study Will Assess Lower Booster Doses As Vaccine-Sparing Measure
In the run-up to a major pandemic preparedness summit in London next month, CEPI has announced a new trial aimed at broadening access to vaccines in lower-income countries and has welcomed fresh funding for its plan to cut vaccine development times to 100 days.
Company Information
- Industry
- Distributors
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Vaccines
- Other Names / Subsidiaries
-
- China National Medical Device Co., Ltd. (CMIC)
- China National Pharmaceutical Industry Co., Ltd. (Sinopharm CNPIC)
- China National Scientific Instruments & Materials Corporation (Sinopharm CSIMC)
- China Sinopharm International Corporation (Sinopharm International)
- Sinopharm A-THINK Pharmaceutical Co., Ltd
- Sinopharm Group Company Limited